Literature DB >> 21288812

Genotypic tests for determining coreceptor usage of HIV-1.

Daniel R Kuritzkes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21288812      PMCID： PMC3071061          DOI： 10.1093/infdis/jiq034

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  8 in total

1.  Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Authors:  Luke C Swenson; Theresa Mo; Winnie W Y Dong; Xiaoyin Zhong; Conan K Woods; Mark A Jensen; Alexander Thielen; Douglass Chapman; Marilyn Lewis; Ian James; Jayvant Heera; Hernan Valdez; P Richard Harrigan
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

3.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Authors:  David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin Dejesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna Van Der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

4.  Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Authors:  Zhaohui Su; Roy M Gulick; Amy Krambrink; Eoin Coakley; Michael D Hughes; Dong Han; Charles Flexner; Timothy J Wilkin; Paul R Skolnik; Wayne L Greaves; Daniel R Kuritzkes; Jacqueline D Reeves
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

5.  A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

Authors:  Michael Saag; James Goodrich; Gerd Fätkenheuer; Bonaventura Clotet; Nathan Clumeck; John Sullivan; Mike Westby; Elna van der Ryst; Howard Mayer
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

6.  Maraviroc for previously treated patients with R5 HIV-1 infection.

Authors:  Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 91.245

Review 7.  Tropism testing in the clinical management of HIV-1 infection.

Authors:  Nina H Lin; Daniel R Kuritzkes
Journal:  Curr Opin HIV AIDS       Date:  2009-11       Impact factor: 4.283

8.  Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.

Authors:  Athe M N Tsibris; Bette Korber; Ramy Arnaout; Carsten Russ; Chien-Chi Lo; Thomas Leitner; Brian Gaschen; James Theiler; Roger Paredes; Zhaohui Su; Michael D Hughes; Roy M Gulick; Wayne Greaves; Eoin Coakley; Charles Flexner; Chad Nusbaum; Daniel R Kuritzkes
Journal:  PLoS One       Date:  2009-05-25       Impact factor: 3.240
  8 in total
  2 in total

Review 1.  HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Authors:  Michele W Tang; Robert W Shafer
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

2.  Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death.

Authors:  Maria Casadellà; Alessandro Cozzi-Lepri; Andrew Phillips; Marc Noguera-Julian; Markus Bickel; Dalibor Sedlacek; Kai Zilmer; Bonaventura Clotet; Jens D Lundgren; Roger Paredes
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.